公司业务与结构 - 公司是制药和医疗器械行业的主要参与者 近期市值接近4250亿美元[2] - 公司曾运营强大的消费者健康部门 生产泰诺和创可贴等知名产品 该部门于2023年分拆为独立公司Kenvue[3] 财务表现 - 第二季度收入同比增长5.8% 收益增长18%[2] - 季度股息为每股1.30美元 股息收益率为2.95%[5] 产品研发管线 - 产品组合包括免疫学治疗药物Stelara和Tremfya 以及癌症药物Darzalex和Erleada[4] - 拥有40个项目处于后期临床试验阶段 评估新候选药物并为现有治疗药物寻求额外批准[4] 股息记录 - 拥有63年股息增长记录 使其成为最佳派息股票之一[5] - 被列入12只最佳现时买入派息股票名单[1]

Organizational structure in a business plan outlines how your company is arranged, defining roles, responsibilities, and reporting relationships. It’s crucial for establishing a clear hierarchy and departmentalization, which improve communication and decision-making. Comprehending different structures, such as centralized or decentralized models, can greatly impact operational efficiency. As you explore the various types of organizational structures, you’ll find that each offers unique benefits and challeng ...

A high yield is only one part of the story when it comes to picking dividend stocks.It is tempting for a dividend investor to simply select the highest yielding stocks. The problem with that approach is that it exposes you to the risk of dividend cuts if the yield is too high for the company to support.Which is why dividend lovers also need to consider dividend history as they look at a company. And, when you do that, you'll find that companies like Pfizer (PFE -0.50%), which has a huge 7.2% yield, don't ma ...

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of clinical remission and endoscopic improvement versus placebo at Week 12 with a subcutaneous induction regimen, consistent with IV induction Johnson & Johnson is initiating a head-to-head study seeking to demonstrate the superiority of TREMFYA® vs. Skyrizi® (risankizumab) in Crohn's disease, based on the confiden ...

Regeneron unveiled what it calls "paradigm-shifting" test results for a drug that could prevent patients from developing multiple myeloma. ...

Sector OverviewThe technology sector is driving today's stock market with impressive performances from key players. The semiconductor space shows a mixed bag, with Advanced Micro Devices (AMD) ticking up by 0.75% while Micron Technology (MU) faces a decline of 4.63%. However, the standout in technology is Oracle (ORCL) and Palantir Technologies (PLTR), making significant gains of 1.93% and 2.36%, respectively. This positive momentum is spreading across tech, bolstered by a robust showing from Microsoft (MSF ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in updated results from the Phase 2 MajesTEC-5 study TORONTO , Sept. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple mye ...

An updated edition of the July 31, 2025 article.The concept of a wide moat refers to companies that possess strong, lasting competitive advantages, which insulate them from competition and enable them to sustain long-term profitability. The term, popularized by Warren Buffett, likens a company’s market position to a medieval castle surrounded by a wide moat — difficult for rivals to cross and attack.Among the companies recognized for their wide moats, some are Microsoft Corporation (MSFT) , Johnson & Johnso ...

France’s Juisci, a HealthTech startup that transforms the way healthcare professionals consume scientific knowledge, has secured €5.5 million in Seed funding in order to boost R&D, scale its team, and accelerate international expansion, with a strong focus on the U.S. market.The round was led by Big Pi Ventures, with participation from Ring Capital, Bpifrance, and strategic business angels.“Doctors don’t need more information – they need quick, trustworthy access to science. Juisci gives them back time and ...